PASCAL mitral valve repair system versus MitraClip: comparison of transcatheter edge-to-edge strategies in complex primary mitral regurgitation

[1] Feldman T(2015)Randomized comparison of percutaneous repair and surgery for mitral regurgitation: 5-year results of EVEREST II J Am Coll Cardiol 66 2844-2854

[2] Kar S(2017)2017 ESC/EACTS Guidelines for the management of valvular heart disease Eur Heart J 38 2739-2791

[3] Elmariah S(2017)Compassionate use of the PASCAL transcatheter mitral valve repair system for patients with severe mitral regurgitation: a multicentre, prospective, observational, first-in-man study Lancet (London, England) 390 773-780

[4] Baumgartner H(2020)2020 Focused Update of the 2017 ACC Expert Consensus Decision Pathway on the management of mitral regurgitation: a report of the American College of Cardiology Solution Set Oversight Committee J Am Coll Cardiol 75 2236-2270

[5] Falk V(2017)Assessing observer variability: a user's guide Cardiovasc Diagn Ther 7 317-324

[6] Bax JJ(2015)Clinical Trial design principles and endpoint definitions for transcatheter mitral valve repair and replacement: part 2: endpoint definitions: a consensus document from the mitral valve academic research consortium J Am Coll Cardiol 66 308-321

[7] Praz F(2014)MitraClip therapy in surgical high-risk patients: identification of echocardiographic variables affecting acute procedural outcome JACC Cardiovasc Interv 7 394-402

[8] Spargias K(2017)Impact of residual mitral regurgitation after MitraClip implantation Int J Cardiol 227 813-819

[9] Chrissoheris M(2016)What is a "good" result after transcatheter mitral repair? Impact of 2+ residual mitral regurgitation J Thorac Cardiovasc Surg 151 88-96

[10] Bonow RO(2020)degenerative mitral valve repair restores life expectancy Ann Thorac Surg 109 794-801

[1] Feldman T(2015)Randomized comparison of percutaneous repair and surgery for mitral regurgitation: 5-year results of EVEREST II J Am Coll Cardiol 66 2844-2854

[2] Kar S(2017)2017 ESC/EACTS Guidelines for the management of valvular heart disease Eur Heart J 38 2739-2791

[3] Elmariah S(2017)Compassionate use of the PASCAL transcatheter mitral valve repair system for patients with severe mitral regurgitation: a multicentre, prospective, observational, first-in-man study Lancet (London, England) 390 773-780

[4] Baumgartner H(2020)2020 Focused Update of the 2017 ACC Expert Consensus Decision Pathway on the management of mitral regurgitation: a report of the American College of Cardiology Solution Set Oversight Committee J Am Coll Cardiol 75 2236-2270

[5] Falk V(2017)Assessing observer variability: a user's guide Cardiovasc Diagn Ther 7 317-324

[6] Bax JJ(2015)Clinical Trial design principles and endpoint definitions for transcatheter mitral valve repair and replacement: part 2: endpoint definitions: a consensus document from the mitral valve academic research consortium J Am Coll Cardiol 66 308-321

[7] Praz F(2014)MitraClip therapy in surgical high-risk patients: identification of echocardiographic variables affecting acute procedural outcome JACC Cardiovasc Interv 7 394-402

[8] Spargias K(2017)Impact of residual mitral regurgitation after MitraClip implantation Int J Cardiol 227 813-819

[9] Chrissoheris M(2016)What is a "good" result after transcatheter mitral repair? Impact of 2+ residual mitral regurgitation J Thorac Cardiovasc Surg 151 88-96

[10] Bonow RO(2020)degenerative mitral valve repair restores life expectancy Ann Thorac Surg 109 794-801